Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
Type:
Grant
Filed:
May 2, 2006
Date of Patent:
March 20, 2007
Assignee:
Avanir Pharmaceuticals
Inventors:
Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.
Abstract: An anti acid-fast bacterial agent containing, as an active ingredient, a pyridonecarboxylic acid derivative represented by the following general formula (1), a salt thereof, or a hydrate thereof, which shows excellent antibacterial activity against Mycobacterium tuberculosis and atypical acid-fast bacteria and exhibits good pharmacokinetics and safety
Abstract: The invention provides compounds of the general formula: wherein X is selected from the group consisting of oxygen, sulfur and nitrogen-containing groups selected from azine, oxime, hydrazone, aromatic hydrazone, aliphatic hydrazone, semicarbazone, guanidinyl group, and aliphatic or aromatic imines; Y is selected from the group of halogens; R1 and R2 are independently selected from the group consisting of H, lower alkyl group (of C1 up to C6), lower hydroxyalkyl group (of C1 up to C6), lower O-alkyl group (of C1 up to C6), lower alkylcarbonyl group (of C2 up to C6), lower alkyloxycarbonyl group (of C1 up to C6), haloalkylcarbonyl group (of C1 up to C6), or arylsulfonyl group, and their pharmaceutically acceptable salts. The compounds are useful as active ingredients in pharmaceutical compositions. The invention relates to the use of the said compounds as a medicament, in particular as an antibiotic.
Type:
Grant
Filed:
March 20, 2002
Date of Patent:
February 13, 2007
Assignee:
Dar Al Dawa Development and Investment Co.
Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
Type:
Grant
Filed:
May 24, 2002
Date of Patent:
September 12, 2006
Assignee:
Avanir Pharmaceuticals
Inventors:
Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Mumar K. C.
Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
Type:
Grant
Filed:
November 7, 2005
Date of Patent:
August 1, 2006
Assignee:
Avanir Pharmaceuticals
Inventors:
Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.
Abstract: Compounds of the following formula (I): where a, b, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
Type:
Grant
Filed:
September 22, 2004
Date of Patent:
February 7, 2006
Assignee:
Schering Aktiengesellschaft
Inventors:
Judi A. Bryant, Brad O. Buckman, Imadul Islam, Raju Mohan, Michael M. Morrissey, Guo Ping Wei, Wei Xu, Shendong Yuan
Abstract: The invention refers to the use of a lacrophyl preparation containing lysozyme, tris(hydroxymethyl)aminomethane, if desired other lacrophyl components, preferably ascorbic acid and/or citric acid and/or ethylenediamine-tetraacetic acid, in the rest distilled water for the dissolution of an active substance being insoluble or only slightly soluble in water or physiological saline, for preparing eye-drops, and/or in case of eye-drops containing an active substance to adjust optionally an active substance medium appropriate to the composition of the native tear and for the microbiological protection of the medium.
Abstract: The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological function in these patients.
Type:
Grant
Filed:
April 17, 2003
Date of Patent:
May 10, 2005
Assignee:
Vanderbilt University
Inventors:
Charles W. Stratton, William M. Mitchell, Subramaniam Sriram
Abstract: An antibacterial formulation suitable for injection into animals containing approximately 2-10% w/v difloxacin HCl, L-arginine base, propylene glycol, ethanol and/or benzyl alcohol, and water. The formulation is a solution having a pH of form 9 to 10. The formulation produces little or no tissue damage or irritation at the injection site.
Abstract: Compounds of the following formula (I): where a, b, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
Type:
Grant
Filed:
June 5, 2002
Date of Patent:
March 1, 2005
Assignee:
Schering Aktiengesellschaft
Inventors:
Judi A. Bryant, Brad O. Buckman, Imadul Islam, Raju Mohan, Michael M. Morrissey, Guo Ping Wei, Wei Xu, Shendong Yuan
Abstract: The invention relates to inhalable quinolonecarboxylic acid derivative compositions for local control of diseases of the respiratory organs, in particular of lung diseases.
Type:
Application
Filed:
February 10, 2004
Publication date:
December 16, 2004
Applicant:
Bayer HealthCare AG
Inventors:
Rainer Endermann, Harald Labischinski, Christoph Ladel, Uwe Petersen, Ben Newton
Abstract: This invention relates to compounds which are useful as enhanced propertied pharmaceutical compounds for both human and veterinary application. The pharmaceutical compounds which are suitable for use in this invention are those compounds which can be substituted with a moiety, said moiety comprising a substituent which enhances or changes the properties of the pharmaceutical compound. The chemical modification of drugs into labile derivatives with enhanced physicochemical properties that enable better transport through biological barriers is a useful approach for improving-drug delivery.
Type:
Application
Filed:
December 17, 2002
Publication date:
December 16, 2004
Inventors:
Mark Joseph Mulvihill, Steven Howard Shaber
Abstract: The invention relates to novel compounds of formula (I) having affinity for the 5-HT6 receptor preparation, to compositions containing them and their use in the treatment of various disorders, including CNS disoders.
Type:
Application
Filed:
February 6, 2004
Publication date:
December 2, 2004
Inventors:
Steven Mark Bromidge, Christopher Norbert Johnson, Gregor James MacDonald, Mervyn Thompson, David R Witty
Abstract: A fullerene-antibiotic conjugate including at least one antibiotic molecule per fullerene moiety. The fullerene may comprise C60 and the antibiotic may comprise vancomycin or may be selected from the group consisting of penicillins, cephalosporins, quinolones, fluoroquinolones, macrolides, lincosamines, carbepenems, conobactams, aminoglycosides, glycopeptides, tetracyclines, sulfonamides, rifampin, oxazolidonones, and streptogramins. The conjugate preferably includes at least two and more preferably at least three antibiotic molecules per C60 center. A method for making a fullerene(C60)-antibiotic conjugate, comprises: synthesizing a linker precursor (I); reacting the linker precursor (I) with C60 via a Bingel-reaction, to produce a fullerene-linker conjugate (II); hydrolyzing the fullerene-linker conjugate (II), resulting in a desired derivative of C60 (III); and reacting the derivative (III) with a desired antibiotic to produce a fullerene-antibiotic conjugate (IV).
Type:
Application
Filed:
February 11, 2004
Publication date:
December 2, 2004
Applicant:
William Marsh Rice University
Inventors:
Lon J. Wilson, Andrey L. Mirakyan, Matthew P. Cubbage
Abstract: The present invention relates to a method for treating bacterial infections, preferably infections caused by FimH expressing bacteria, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote detah of IL-3 dependent cells cultured to presence of IL-3.
Abstract: Disclosed are pharmaceutical preparations for use in the therapeutical and prophylactic treatment of bacterial and parasitic infections, especially malaria. The preparations contain as active substances 3-N-formyl-hydroxylaminopropyl phosphonic acid derivatives or 3-N-acetylhydroxylaminopropyl phosphonic acid derivatives and may be combined with other pharmaceutical active agents and/or other pharmaceutically acceptable excipients. Also disclosed are methods of treatments using such preparations.
Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, including Mycoplasma bacteria, such as Mycoplasma pneumoniae.
Type:
Application
Filed:
April 2, 2004
Publication date:
November 18, 2004
Applicant:
SmithKline Beecham Corporation
Inventors:
Donna M. Crabb, Lynn B. Duffy, Karen B. Searcy
Abstract: A wet granulation formulation for oral dosage forms containing a non-hydrated quinoline carboxylic acid type antibacterial agent with low water content and non-hygroscopic properties.
Type:
Application
Filed:
March 9, 2004
Publication date:
November 11, 2004
Applicant:
The Jordanian pharmaceutical manufacturing Co.
Inventors:
Adnan Badwan, Lina Najati Nabulsi, Mahmoud M. Omari
Abstract: Methods of treating, preventing and/or managing myclodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Abstract: A pharmaceutical composition is provided comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax, and (c) a pharmaceutically acceptable non-aqueous carrier; and having an antibacterial substance in an antibacterially effective amount stably dispersed in the vehicle. The composition is suitable for administration by intramammary infusion to a milk producing animal for treatment and/or prevention of mastitis or other diseases of the udder, as well as for otic administration for treatment and/or prevention of an ear infection.
Type:
Application
Filed:
October 17, 2003
Publication date:
October 28, 2004
Inventors:
Nancy Jean Britten, Niki Ann Waldron, John W. Burns
Abstract: A method is provided for treatment of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering an antibacterial agent to the organ via the exterior orifice and administering in combination therapy with the antibacterial agent a second agent that is an anti-inflammatory agent, an analgesic and/or an antipyretic. The antibacterial agent and, optionally, the second agent, are administered as a pharmaceutical composition further comprising a vehicle that comprises an amphipathic oil that is water dispersible and ethanol insoluble, microcrystalline wax and a pharmaceutically acceptable non-aqueous carrier. Also provided is such a composition comprising the antibacterial agent and the second agent.
Type:
Application
Filed:
March 5, 2004
Publication date:
October 28, 2004
Inventors:
Nancy Jean Britten, Niki Ann Waldron, Jeffrey L. Watts, John Walter Hallberg, John W. Burns
Abstract: A method of modulating the activity of a aberrant cell topoisomerase enzyme involving contacting the enzyme with a compound that inhibits enzyme-mediated cleavage of a polynucleotide substrate with which the enzyme is in complex. Pharmaceutical compositions containing such compounds may be used to treat neoplasias or to inhibit the growth of certain cancer cells. Screening methods can be employed to identify other compounds for these uses.
Abstract: Provided are novel crystalline forms of gatifloxacin, denominated forms L, M, P, Q, S, and T1, and methods for making them. Also provided are methods of transforming the novel crystalline forms of gatifloxacin of the present invention to other crystalline forms of gatifloxacin.
Type:
Application
Filed:
August 6, 2003
Publication date:
September 30, 2004
Inventors:
Valerie Niddam-Hildesheim, Shlomit Wizel, Greta Sterimbaum
Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against maxillary sinus pathogenic pathogenic bacteria
Abstract: This invention relates to a method for coating a medical device comprising the steps of applying to at least a portion of the surface of said medical device, an antimicrobial coating layer and a non-pathogenic bacterial coating layer, wherein the antimicrobial and non-pathogenic bacterial coating layers inhibit the growth of pathogenic bacterial and fungal organisms. The non-pathogenic bacterium used in the bacterial coating layer is resistant to the antimicrobial agent. Furthermore, the non-pathogenic bacterium layer includes at least one of the following: viable whole cells, non-viable whole cells, or cellular structures or extracts. The antimicrobial agent and non-pathogenic bacterium are used to develop a kit comprising these compositions in one container or in separate containers. The kit is used to coat a catheter prior to implantation in a mammal.
Abstract: The present invention provides a medicinal composition comprising (1) a pharmacologically active substance, (2) a drug absorbefacient and (3) a taurine compound or a polyamine. A taurine compound has an efect of suppressing or preventing damage of the intestinal mucous membrane, and therefore adding the taurine compound to a medicinal composition containing a pharmacologically active substance and a drug absorbefacient makes it possible to suppress or prevent damage of the intestinal mucosa. A polyamine improves the absorbability of pharmacologically active substances, and therefore adding the polyamine to a medicinal composition containing a pharmacologically active substance and a drug absorbefacient makes it possible to decrease the dose of the drug absorbefacient, thereby suppressing or preventing damage of the intestinal mucosa.
Abstract: This invention relates to certain cyclic amine derivatives of Formula (I)
that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
Type:
Grant
Filed:
August 29, 2001
Date of Patent:
August 3, 2004
Assignee:
Syntex (U.S.A.) LLC
Inventors:
Leyi Gong, Donald Roy Hirschfeld, Denis John Kertesz, David Bernard Smith, Francisco Xavier Talamas, Robert Stephen Wilhelm
Abstract: The present invention provides methods and compositions useful for preventing bacteremia by decolonizing the intestinal tract of a patient. Although the present invention is useful for preventing bacteremia by any Gram-positive bacteria, it is particularly useful against antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide intermediary susceptible Staphylococcus aureus (GISA), and penicillin-resistant Streptococcus pneumoniae (PRSP). Decolonization therapy using the methods and compositions of this invention are also useful for preventing a Gram-negative bacteremia.
Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria.
Type:
Application
Filed:
January 15, 2004
Publication date:
July 29, 2004
Applicant:
SmithKline Beecham Corp.
Inventors:
Darrin Bast, Ross J. Davidson, Joyce DeAzavedo, Donald E. Low
Abstract: Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.
Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria.
Abstract: The invention relates to aqueous infusion solutions of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid (ciprofloxacin) which are stable in storage and which can be obtained by mixing between 0.015 and 0.5 g of active ingredient for 100 ml of aqueous solution with sulphuric acid or sodium hydrogen sulfate in a quantity equal to or less than 0.96 mole per mole of active ingredient, sufficient for dissolving the active ingredient and stabilizing the solution. The invention also relates to methods for producing the infusions and the use thereof. The inventive infusions enable the acid content to be reduced, are more stable in storage with the same acid content than other known solutions, and enable a larger proportion of secondary components to be tolerated in the active ingredient than previous standard infusions of ciprofloxacins.
Type:
Application
Filed:
September 11, 2003
Publication date:
April 29, 2004
Inventors:
Klaus Sommermeyer, Hans-Jorg Muller, Tilo Hniopek, Bernd Eschenbach
Abstract: The invention consists of a stable preparation of a combination drug, comprising of an anti-inflammatory agent and an anti-infective agent. The anti-inflammatory agent in this invention is a corticosteroid, and the anti-infective agent is a derivative of quinolone, amino-glycoside or their pharmaceutically acceptable salts. The combination drug essentially comprises of i) an anti-inflammatory agent which is a corticosteroid, ii) an anti-infective agent selected from the group comprising of derivatives of quinolone, aminoglycoside and their pharmaceutically acceptable salts; iii) a complexation enhancing polymer; iv) a solubiliser exhibiting an inclusion phenomenon, along with pharmaceutically acceptable excipients with a suitable carrier system.
Type:
Application
Filed:
October 20, 2003
Publication date:
April 22, 2004
Inventors:
Mohan A. Chandavarkar, Nandan M. Chandavarkar, Mainde Chandrashekhar
Abstract: The invention describes an antibiotic coating for porous bodies and its use. Into the porous system of non-metallic porous bodies and of metallic porous bodies, a coating made of at least one antibiotic salt that is hardly soluble in water or in an aqueous environment from the group of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate, the kanamycin dodecyl sulfate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the ciprofloxacin myristate, the vancomycin dodecyl sulfate, the vancomycin laurate, the vancomycin myristate, the vancomycin teicoplanin and the clindamycin teicoplanin is introduced. The antibiotically coated, porous bodies are used as implants.
Type:
Application
Filed:
June 20, 2003
Publication date:
March 11, 2004
Applicant:
Heraeus Kulzer GmbH & Co.KG
Inventors:
Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kuhn
Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pnemoniae and rare H. influenzae strains.
Type:
Application
Filed:
March 24, 2003
Publication date:
March 4, 2004
Applicant:
SmithKline Beecham Corporation
Inventors:
Peter C. Appelbaum, Kim L. Credito, Todd Davies, Diane B. Hoellman, Linda M. Kelly, Glenn A. Pankuch
Abstract: Disclosed are guanidine and biguanidine derivatives which have anti-viral and anti-bacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds.
Abstract: A method is provided for treatment of an infective condition in an udder of a milk producing animal. The method comprises intramammary administration of an antibacterial agent in combination therapy with a selective COX-2 inhibitor in therapeutically effective amounts of each. Also provided is a pharmaceutical composition comprising an antibacterial agent and a selective COX-2 inhibitor, together with one or more excipients, in a dosage form suitable for intramammary administration to a milk producing animal.
Type:
Application
Filed:
March 20, 2003
Publication date:
February 19, 2004
Inventors:
Nancy J. Britten, Niki A. Waldron, Jeffrey L. Watts, John W. Hallberg
Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria.
Abstract: Methods and pharmaceutical compositions for preventing and treating disease mediated by toxin-secreting bacteria. Inventive methods and compositions are suited to preventing or treating infections caused by bacterial toxins that enter host cells via receptor-mediated endocytosis (e.g., the anthrax and diphtheria toxins). Methods comprise a step of administering to an individual a pharmaceutical composition that includes an effective amount of an inhibitor of endosomal acidification. The inhibitor may be a primary amine, a carboxylic ionophore, or a selective inhibitor of the vacuolar proton pump (V-ATPase). The inhibitors of endosomal acidification may be employed in combination with other therapeutics such as antibiotics and antitoxins in order to prevent, treat or cure the disease.
Abstract: The present invention is based on the finding that sigma receptor ligands can modulate endothelial cell proliferation and/or survival, and hence control angiogenesis, and in particular that sigma receptor ligand antagonists can be used to inhibit angiogenesis aid so treat conditions such as psoriasis, diabetic retinopathy and cancer. Exemplary compounds include IPAG and rimcazole.
Type:
Application
Filed:
June 5, 2003
Publication date:
January 29, 2004
Inventors:
Barbara Ann Spruce, Suzanne Amy Eccles, Michael Dexter
Abstract: A method for treating cellular and tissue damage is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof in the prevention and treatment of dysfunction, damage, and/or injuries to organs, tissues and/or cells in human or animal subjects caused by diseases, infections and conditions such as pneumonia, coronavirus, multiple transfusions, trauma, ischemic-reperfusion dysfunctions, stroke, drug overdose, and severe acute respiratory syndrome. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics. The acid may be administered in any practical delivery form, and in free acid or buffered form.
Type:
Application
Filed:
July 18, 2003
Publication date:
January 29, 2004
Inventors:
Karen Stec, Israel Rubinstein, David Eiznhamer, Ze-Qu Xu, Michael Flavin
Abstract: The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in diagnosing arthritis conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, or delaying the onset of arthritis conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.
Abstract: Provided are novel crystalline forms of gatifloxacin denominated forms A, B, C, D, E1, F, G, H, I, and J, and methods for their preparation. Also provided are methods for making known crystalline forms of gatifloxacin, in particular forms omega and T2RP.
Type:
Application
Filed:
May 12, 2003
Publication date:
January 15, 2004
Inventors:
Valerie Niddam-Hildesheim, Shlomit Wizel, Greta Sterimbaum, Ehud Amir
Abstract: The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological function in these patients.
Type:
Application
Filed:
April 17, 2003
Publication date:
December 4, 2003
Inventors:
Charles W. Stratton, William M. Mitchell, Subramaniam Sriram
Abstract: The topical application of an azalide antibiotic such as azithromycin to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a depot for sustained release. A more convenient dosing regimen can also be provided by the use of an appropriate depot. Furthermore, a composition containing a combination of medicaments is also provided.
Abstract: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent.